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Methods. This prospective US multicenter trial of leuprolide acetate 1-month depot (7.5–15mg) for central precocious puberty
utilized an open-label treatment period, long-term follow-up, and adult callback. Forty-nine females <9 years old with Tanner
breast stage ≥2 before 8 years and 6 males <10 years old with Tanner genital stage ≥2 before 9 years with stimulated LH ≥10IU/L
and bone age advance ≥1 year were enrolled. Results. Subjects were treated for 3.9 ± 2.0 years. Mean peak GnRH-stimulated LH
and FSH were prepubertal after the ﬁrst dose and remained suppressed throughout treatment. During treatment, mean estradiol
decreased tothelimitofdetection and mean testosteronedecreased butremained above prepubertal norms.Duringposttreatment
follow-up (3.5 ± 2.2 years), all patients achieved a pubertal hormonal response within 1 year and menses were reported in all
females ≥12 years old. No impairment of reproductive function was observed at adulthood (mean age: 24.8 years).
1.Introduction
Childrenwithcentralprecociouspuberty(CPP)prematurely
develop pubertal pulsatile release of gonadotropin-releasing
hormone (GnRH), leading to an increase in gonadotropin
and sex steroid levels, development of secondary sexual
characteristics, advancement of bone age (BA), and conse-
quent reduction in adult height (AH) [1]. Treatment goals
include hormonal suppression, cessation of development of
secondary sex characteristics, halting or preventing menar-
che, and preservation of AH. If left untreated, children
with CPP can also face psychological challenges resulting
fromprematurephysicalmaturationthatcontrastswiththeir
immature emotional development [2].
GnRH analogs (GnRHa) have been the standard of care
for CPP for over 15 years [1]. Continuous exposure to
GnRHa desensitizes pituitary gonadotroph receptors and
suppressesluteinizinghormone(LH)andfolliclestimulating
hormone (FSH) secretion. Eﬃcacy of various GnRHa in
CPP has been established [3–14], but truly long-term studies
are limited, particularly for leuprolide. Furthermore, most
GnRHa studies have not utilized sensitive gonadotropin
assays that can accurately assess the extent of hormonal
suppression. The objectives of this open-label treatment
study of leuprolide acetate 1-month depot and long-term
observational extension study were to evaluate the suppres-
sion of the pituitary-gonadal axis and the clinical sexual
characteristics during treatment and to examine the long-
term impact on the growth pattern, AH, and reproductive
function of children treated for CPP. Initial results from the
treatment period led to FDA approval of leuprolide acetate
1-month depot for the treatment of CPP. Here we report
hormonal suppression during the treatment period, safety,
recovery of hormone secretion, and long-term reproductive
outcomes.Aseparatepaperreportstheauxologicaloutcomes
[15].
2. Patients andMethods
2.1. Patients. All patients were na¨ ıve to GnRHa therapy.
Females with Tanner breast stage ≥2 before 8.0 years old and
chronological age (CA) <9.0 years at initiation of therapy2 International Journal of Pediatric Endocrinology
and males with Tanner genital stage ≥2 before 9.0 years
and CA <10.0 years were eligible. Inclusion criteria included
GnRH-stimulated peak LH ≥10IU/L, BA advance ≥1y e a r
beyond CA by Fels Method [16], no prior treatment with
GnRHa,nohistoryofcentralnervoussystemirradiation,and
anticipatedtreatmentfor ≥1year.PatientshadanMRIofthe
brain, hypothalamus, and pituitary prior to the initiation of
therapy. Institutional review board approval was obtained at
each site, and written informed consent was provided by the
subject and the subject’s parent or legal guardian prior to any
study-related procedures.
2.2. Methods. This study at 9US centers consisted of an
open-labeltreatmentperiodwithleuprolideacetate1-month
depot and a long-term follow-up period. Clinical sexual
characteristics, LH, FSH, and sex steroids during and after
treatment were assessed. After a screening visit, treatment
period study visits occurred at week 0, 4, 8, 12, 24, 36,
and 48, and then every 24 weeks. Study visits included
a physical examination with Tanner staging, weight, and
triplicate heights by stadiometer. Laboratory assessments
included GnRH stimulation testing to determine basal and
peak stimulated LH and FSH using Factrel 100µgI Vw i t h
blood samples at 0, 20, 40, 60, and 90 minutes. LH and
FSH were measured by dissociation-enhanced lanthanide
ﬂuorescence immunoassay (DELFIA), with a sensitivity of
0.15IU/L for LH and 0.5IU/L for FSH (University of
Pittsburgh Children’s Hospital; Pittsburgh, PA). Estradiol
(or testosterone) levels were obtained at 0 and 90 min-
utes and were measured by radioimmunoassay (University
of Pittsburgh Children’s Hospital, Pittsburgh, PA) with a
lower limit of 18.36pmol/L (5pg/mL) for estradiol and
0.347nmol/L (10ng/dL) for testosterone. Hematology and
chemistry analyses were performed by Covance (formerly
Scicor, Indianapolis, IN). Adverse events were assessed at
each study visit. Treatment-emergent adverse events were
coded using the Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART) dictionary.
Leuprolide acetate 1-month depot was started at a dose
of at least 300µg/kg (7.5, 11.25, or 15.0mg) administered
intramuscularly (IM) every 28 days. Incremental dose
adjustments of 3.75mg were made at each clinic visit for
speciﬁc criteria or for weight increase. Doses were increased
at the week 8 study visit if the peak LH value from the
week 4 GnRH stimulation test exceeded 1.75IU/L. At week
12 and beyond, doses were to be increased for peak LH
value >1.75IU/L, testosterone >0.347nmol/L (10ng/dL),
estradiol >18.36pmol/L (5pg/mL), or menstrual bleeding or
spotting. Therapy was discontinued at an age appropriate for
reinitiation of puberty at the discretion of the investigator.
After discontinuation of treatment, patients could enter
a long-term observational follow-up study with visits occur-
ring every 6 months (1 month equal to 28 days) until labo-
ratory measurements reached pubertal levels, then annually
until the age of 21 years. Follow-up study visits included
Tanner staging, height and weight, and a questionnaire
on menstrual history. Basal and stimulated gonadotropins
and estradiol/testosterone were measured at each visit until
a pubertal response was observed; thereafter only basal
levels were measured. Pubertal response was deﬁned by
all of the following: females, peak LH >6IU/L, peak FSH
≥5IU/L,estradiol ≥55.1pmol/L(15pg/mL);males,peakLH
>10IU/L, peak FSH ≥2.5IU/L, testosterone ≥2.60nmol/L
(75ng/dL). Menses was deﬁned as ≥3 consecutive days of
uterine bleeding. A ﬁnal visit at adulthood was conducted to
assess adult height and reproductive function by question-
naire and pelvic ultrasound.
2.3. Statistics. Clinical suppression was deﬁned as an
improvement or no change in Tanner staging. The devel-
opment of clinical sexual characteristics posttreatment was
deﬁned as an increase in Tanner stage from the end of
treatment. Patients who entered the study at Tanner stage 5
were not included in these analyses. Summary statistics were
calculated for age, menses, adverse events, and gonadotropin
and sex steroid levels. For levels below the detection thresh-
olds, calculations substituted the relevant threshold value.
Standard deviations or ranges (parentheses) are reported in
text. Signiﬁcance tests for change versus no change were
performed using paired t-tests.
3. Results
Subjects were treated for an average of 3.9 ± 2.0 years and
followed for an average posttreatment period of 3.5 ± 2.2
years.
3.1. Baseline Characteristics. Fifty-ﬁve patients, na¨ ıve to
GnRHa treatment, met the inclusion criteria of peak LH
≥10IU/L and BA advance ≥1 year and entered the study.
Subject demographics and baseline characteristics for the
female (n = 49) and male (n = 6) patients are summarized
in Table 1. Twenty patients (18/49 females and 2/6 males)
hadahistoryofneurologicaldisorder,includingheadtrauma
(n = 4), seizure disorder (n = 2), suprasellar cyst (n = 2),
meningitis (n = 2), hypothalamic tumor, hamartoma, spina
biﬁda, hydrocephalus, developmental delay, and hypotonia
(all n = 1). The remaining patients (35/55) were diagnosed
with idiopathic CPP.
Mean peak GnRH-stimulated LH was 35.1 ± 21.32IU/L
at baseline. The peak LH occurred at the 20- or 40-
minute blood draw in 51/55 subjects, and in all patients
the diagnostic threshold of 10IU/L was surpassed at both
timepoints. Mean basal LH was 1.98IU/L (range: <0.15–
11.1);6/55pretreatmentbasalLHlevelswere<0.5IU/L.Peak
LH and basal LH were moderately correlated (r = 0.322),
but peak LH was more strongly correlated with peak FSH
(r = 0.652). Serum estradiol levels at 0 and 90 minutes
were undetectable (<18.36pmol/L (5pg/mL)) in 16/49 and
21/49 females, respectively. The 0- and 90-minute mean
estradiol concentrations were 56.9pmol/L (15.5pg/mL) and
56.2pmol/L (15.3pg/mL), respectively. In males, 0- and 90-
minute mean testosterone concentrations were 6.9nmol/L
(199.8ng/dL) and 12.1nmol/L (347.7ng/dL), respectively
(P = .023).
3.2. Treatment Period: Females. Mean age entering the study
was7.3 ±1.9years,meanageatdiscontinuationoftreatmentInternational Journal of Pediatric Endocrinology 3
Table 1: Subject demographics and baseline characteristics.
Characteristic Female subjects Male subjects
N = 49 N = 6
Race, n
Caucasian 30 4
African American 11 0
Asian 0 1
Hispanic 8 1
Age, years
Mean (SD) 7.3 (1.9) 7.9 (2.0)
Range 1.2–9.4a 4.1–9.5
Weight, kg
Mean (SD) 33.6 (9.72) 32.4 (8.96)
Range 13.0–52.2 19.9–41.8
Height, cm
Mean (SD) 131.6 (15.0) 134.4 (18.1)
Range 84.6–154.7 106.7–156.8
Height standardized score
Mean (SD) 1.5 (1.29) 1.4 (1.75)
Range −1.4–3.4 −0.4–4.3
Tanner stage, n
Breast/genitalia I 1b 0
II 9 2
III 25 3
IV 13 1
V1 0
Basal LH, IU/L
Mean (SD) 2.0 (2.06) 1.6 (0.77)
Range <0.15–11.1 0.73–2.6
Peak LH, IU/L
Mean (SD) 36.7 (21.8) 21.2 (9.1)
Range 12.0–119.2 13.5–38.8
History of menstrual bleeding, n
No 36 —
Yes 12 —
aStart of study drug was delayed beyond 9 years old in one girl.
bA one-year-old patient was enrolled in the trial with breast Tanner stage I
based on qualifying peak stimulated LH (84.7IU/L) and E2 (90pg/mL).
was 11.1 ± 1.1 years (7.3–13.3), and mean treatment dura-
tion was 3.8 years (0.23–9.8). Mean peak GnRH-stimulated
LH and FSH in females declined into the prepubertal range
after the ﬁrst dose and remained suppressed throughout
treatment (Figure 1). Mean peak LH decreased to 0.75IU/L
(<0.15–3.9) by week 4 and numerically decreased after
week 12 (Figure 1(a)). During treatment, 8/49 females had
ap e a ks t i m u l a t e dL Hv a l u e≥1.75IU/L. Mean peak FSH
decreased from 14.0IU/L at baseline to 0.9IU/L (<0.5–
3.19) by week 4 then numerically increased but remained
<1.7IU/L (Figure 1(b)).
Mean basal LH in females decreased from 2.0IU/L at
baseline to 0.48IU/L (<0.15–1.82) at week 4 and numerically
declined during the treatment period (Figure 2(a)). Mean
basal FSH decreased from 4.1IU/L at baseline to 0.8IU/L
(0.15–1.97) by week 4 and was <1.5IU/L for the duration
of treatment (Figure 2(b)). Mean basal estradiol decreased
from57.28pmol/L(15.6pg/mL)atbaselinetothelowerlimit
of detection (18.36pmol/L (5.0pg/mL)) by study week 4.
Almost all postbaseline estradiol levels (99.2%) were below
the threshold of detection.
The mean peak LH:peak FSH ratio in females was 2.6
(1.0–6.2) at baseline, decreased to 0.9 (0.2–3.0) at week
4, and trended downward during the course of treatment
(Figure 3(a)). The mean ratio was ≤0.5 from the second year
onward. The mean basal LH:basal FSH ratio numerically
decreased as treatment progressed (Figure 3(b)), coordinate
with the opposite trends in basal LH and FSH.
Regression or no progression of breast Tanner stage was
observed at week 4 in 81.8% of females. Over 4 years, the
percentage of patients with regression or no progression of
breast stage from baseline at each visit ranged from 66.7% to
90.6%. Uterine bleeding or spotting occurred in 15 females
(31%) during the ﬁrst 4 weeks of treatment (8/15 with
prior history of bleeding). Those 15 girls exhibited a higher
mean serum basal estradiol at baseline compared with the
33 girls who did not have subsequent bleeding (83.2 ± 53.2
pmol/L (22.7 ± 14.5pg/mL) versus 44.1 ± 58.6pmol/L (12.0
± 16.0pg/mL), P = .0325). They also had higher baseline
basalLHlevels(3.46±2.95IU/Lversus1.41 ±1.08IU/L,P<
.001). Uterine bleeding or spotting after week 4 was reported
in 7 females, all in the absence of detectable estradiol.
3.3. Treatment Period: Males. In males, mean start age was
7.9 ± 2.0 years, mean age at discontinuation was 12.4 ± 1.2
years (11.1–14.1), and mean duration was 4.6 years (1.9–
7.9). Mean peak LH decreased from 21.2IU/L at baseline to
0.7IU/L at week 4. During the treatment period, one male
had a peak stimulated LH value ≥1.75IU/L. Mean peak FSH
decreased from 5.6IU/L at baseline to 0.5IU/L at week 4.
Comparable to the females, mean basal LH was suppressed
to 0.5IU/L at week 4 and was ≤0.4IU/L for the duration of
treatment. Mean basal FSH in males decreased from 2.4IU/L
at baseline to 0.5IU/L by week 4 and was ≤0.8IU/L during
the treatment period. Mean basal testosterone decreased
from 6.93nmol/L (199.8ng/dL) at baseline to 0.62nmol/L
(17.8ng/dL) at week 4 and never exceeded 0.84nmol/L
(24ng/dL) during treatment, but 5/6 males had treatment
levels above the prepubertal threshold/limit of detection
of 0.35nmol/L (10ng/dL). Testosterone in 3 males was
intermittently above 1.04nmol/L (30ng/dL), with a max-
imum testosterone of 1.94nmol/L (56ng/dL). Regression
or nonprogression of genital Tanner stage was observed in
5/6 males. Progression from 2 to 3 occurred in the male
with the highest testosterone level and a transient peak LH
≥1.75IU/L.
3.4. Dose Modiﬁcations and Adverse Events during Treatment.
The dose was increased in eight patients. Five were females
with stimulated LH >1.75IU/L, including the 2 youngest
subjects (1 year olds, one with a hamartoma). The dose was
also increased in the male patient with elevated testosterone,
peak LH >1.75IU/L, and Tanner stage progression. All 6
patients suppressed to peak stimulated LH ≤1.75IU/L after4 International Journal of Pediatric Endocrinology
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Figure 1: Mean peak stimulated LH (a, log scale) and FSH (b) for females during the treatment and follow-up periods. Mean concentrations
for peak LH and FSH at each study visit are displayed adjacent to the respective points. Maximum individual concentrations for peak LH at
each study visit are indicated on panel (a). The number of subjects at each study visit is indicated beneath panel (b).
the ﬁrst year. In 2 additional females, a dose adjustment was
made due to weight increase.
Long-term treatment with leuprolide acetate 1-month
depot was well tolerated. There were no clinically relevant
changes in hematology or chemistry values. Adverse events
reported in ≥5% of patients possibly or probably related
to study drug are shown in Table 2. Eleven patients had >1
adverse event related to injections, including reported pain
(n = 8), reaction (n = 3), inﬂammation (n = 2), and/or
edema(n = 1).Noneoftheinjection-siteadverseeventswere
serious or led to premature discontinuation. Two serious
events possibly related to study drug occurred, a severe
asthma exacerbation and an increase in size of a preexisting
optic glioma with deteriorating vision. There was a death
during the study considered unrelated by the investigator, a
cardiopulmonaryarrestfollowingrespiratoryinfection.Nine
patients discontinued study drug prematurely for reasons
including patient request to leave the study, noncompliance
withvisitschedule,losttofollow-up,andthedeathdescribed
above. No patients withdrew due to injection reaction or
failure to achieve adequate suppression.
3.5. Posttreatment Follow-Up Period. Thirty-ﬁve females
entered the posttreatment follow-up period. Most (66.7%)
had breast stage advance by the ﬁrst posttreatment visit.
Tanner breast stage 5 was achieved by 78% of females
within the ﬁrst 3 years of follow-up and in 100% of female
patients within the 5 year follow-up. Mean peak LH andInternational Journal of Pediatric Endocrinology 5
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Figure 2: Mean basal LH (a, log scale) and FSH (b) for females during the treatment and follow-up periods. Mean values for basal LH and
FSH are displayed adjacent to the respective points. Maximum individual concentrations for basal LH at each study visit are indicated on
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FSH concentrations in females increased to 21.3IU/L (0.28–
52.9) and 10.4IU/L (1.2–18.4), respectively, at the 6 month
visit (Figure 1). Mean peak LH:peak FSH ratio rose to 1.9
± 0.9IU/L at the 6 month visit (Figure 3(a)). All females
achieved a pubertal GnRH-stimulated response within 1
year of treatment discontinuation. Mean basal LH increased
to 3.4IU/L (<0.15–9.3) by 6 months posttreatment and to
11.7IU/L in the females who still remained in the study at
the5yearfollow-up(Figure 2(a)).MeanbasalFSHincreased
to 5.4IU/L (0.95–9.3) in females at 6 months and was
5.8IU/L at the 5 year follow-up (Figure 2(b)). Mean basal
LH:basal FSH ratio rose to 0.6 ± 0.3 by the 6 month visit
(Figure 3(b)) and further increased during reestablishment
of puberty, reaching 1.8 ± 1 . 3a tt h e5y e a rv i s i t .M e a n6 International Journal of Pediatric Endocrinology
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estradiol increased to 60.4pmol/L (16.4pg/mL) by 6 months
and to 281.7pmol/L (76.7pg/mL) by 5 years.
Menses were reported for 27/32 female patients during
the follow-up period. The remaining 5 patients were less
than 12 years of age when they discontinued from long-term
follow-up. Mean time from discontinuation to ﬁrst menses
was 1.5 ± 0.5 years (0.5–2.5 years), and the mean age was
12.9 ± 0.9 years (11.6–14.9 years). In those patients who
had menses prior to treatment (n = 7), the average time to
resumption of menses was 1.4 ± 0.5 years (0.5–2.1 years),
and for those patients without menses prior to treatment
(n = 19), elapsed time was 1.6 ± 0.5 years (0.5–2.5 years).
Five males entered the follow-up study, 4 of whom
showed Tanner genital stage advance by 6 months. Mean
peakLHandFSHroseto16.0IU/Land8.7IU/L,respectively,
mean basal LH and FSH were 2.8IU/L and 4.4IU/L, respec-
tively, and basal testosterone was 6.7nmol/L (194ng/dL) at 6
months. All 5 males achieved the deﬁned pubertal response
by 1 year posttreatment.
3.6. Adult Follow-Up. Data to assess reproductive function,
including menstrual cycles, pregnancy, and reported history
of ovarian cysts, were collected in a post-study survey of
20 girls who reached adulthood (ages 18–26). Menstrual
cycles were reported to be normal in 80% of women and
useofbirthcontrolmedicationwasreportedin7/20patients.
Ovarian volumes were assessed by ultrasound in 11 patients
and revealed normal ranges; only small follicular cysts wereInternational Journal of Pediatric Endocrinology 7
Table 2: Adverse events possibly or probably related to study drug
in ≥5% of subjects.
Number of subjects (%)
COSTART term N = 55
Any adverse event 34 (62)
Emotional lability 10 (18)
Injection site pain 8 (15)
Headache 6 (11)
Acne 5 (9)
Pain 4 (7)
Vasodilatationa 4( 7 )
Growth retardedb 4( 7 )
Vaginitis 4 (7)
Injection site reactionc 3( 5 )
Menstrual disorderd 3( 5 )
Weight gain 3 (5)
aVasodilation = ﬂushing and/or hot ﬂashes.
bGrowth retarded = slowing of growth.
cInjection site reaction = injection site reaction, injection site hypersensitiv-
ity, edema, mass, pain, cyst, atrophy, ﬁbrosis, rash, necrosis, inﬂammation,
abscess, hematoma, granuloma, induration.
dMenstrual disorder = menstrual spotting, vaginal bleeding, and cramping.
reported, including in the 2 females with reported polycystic
ovarian syndrome. Twelve pregnancies were reported in 7/20
patients, including multiple pregnancies for 4. There were
6 live births, 5 spontaneous or elective terminations, and 1
ongoing pregnancy; no stillbirths were reported. Four out
of 4 women who attempted to become pregnant became
pregnant. Two women who reported diﬃculty conceiving
had achieved live births.
4. Discussion
Treatment with leuprolide acetate 1-month depot has been
routine therapy for CPP for over 15 years. This report from
the initial US multicenter trial provides details regarding
suppression of gonadotropins and sex steroids during treat-
ment, hormonal and clinical progression during long-term
posttreatment follow-up, and review of reproductive health
at adulthood.
During the treatment period, on average 4 years, leupro-
lide acetate depot rapidly controlled clinical signs of puberty
and suppressed hormones to prepubertal levels. In females,
mean peak LH dropped by over 97% after the ﬁrst injection.
However, the protocol called for an increase in dose for any
peak LH >1.75IU/L, a rigorous outcome measure equivalent
to prepubertal means (17, 18, 21, 22). This resulted in
dose increases in the ﬁrst year of treatment in 6 subjects,
but no stimulated LH levels surpassed this cutoﬀ after the
48 week visit. It is unknown whether that outcome was
solely attributable to duration of treatment or partially to
increases in dose in some patients. Overall, mean peak
LH in females trended downward during therapy, whereas
mean peak FSH trended slightly upward. As a consequence,
the peak LH:peak FSH ratio gradually declined during
therapy, returning subjects to the gonadotropin pattern seen
in normal prepubertal girls.
At baseline, the age, sex ratio, and Tanner stage were
typical of patients with CPP. However, the conservative
entry threshold of peak LH ≥10IU/L, plus the BA advance
criterion, likely excluded some patients who in current
clinicalpracticemightbetreated.Thusthecohortmighthave
been more advanced in puberty than in other CPP studies, as
the mean peak LH of 36IU/L in females and BA advance of
approximately 3 years demonstrate. The relatively advanced
pubertymayexplainthehighpercentageofgirlswithmenses
prior to treatment (25%), which in turn could be linked
to the proportion of girls with bleeding following estrogen
withdrawal in the ﬁrst month (31%). Girls with bleeding
during therapy had higher baseline estradiol and LH levels;
however, a surprising number of girls showed continued
spotting after hormonal suppression was established.
This study was initiated when GnRH for stimulation
testing was still available in the US. The peak LH levels
at diagnosis of CPP were observed in almost all subjects
within 40 minutes after GnRH injection, and with highly
consistent levels among timed samples, supporting the
concept that stimulation testing using multiple samples or
for extended duration is unnecessary [17–19]. Basal LH has
been recommended as a surrogate for peak LH in diagnosis
of CPP [20, 21]; in this study basal LH correlated modestly
with peak LH at diagnosis, although in some subjects the
diagnosticpeakLHwasnotassociatedwithaclearlypubertal
basal LH. Thus, basal LH has reasonable sensitivity as a
screen and perhaps in most instances is adequate to diagnose
CPP [22], while stimulation testing (now using aqueous
leuprolide acetate) may sometimes be required and may help
diﬀerentiate FSH-predominant nonprogressive premature
thelarche from LH-predominant CPP.
The DELFIA LH and FSH assays utilized in the study
are highly sensitive and widely used double-antibody assays
[23]. The rigorous lower LH detection limit of 0.15IU/L was
not relevant at the relatively high concentrations of basal
and peak LH at diagnosis. However, as treatment progressed,
increasing percentages of basal and peak LH levels were at or
below the threshold of detectability. Accordingly, the mean
values for basal and peak LH during therapeutic monitoring
are possibly overstated, as many of the true levels were likely
less than the threshold 0.15IU/L used to calculate the means.
The standard for monitoring the early phase of GnRHa
therapy has been the observation of clinical parameters,
especially pubertal staging and growth rate, and assessment
of peak LH. In the US, the latter now requires blood
obtained after aqueous leuprolide injection or following
leuprolide acetate depot itself [17]. For convenience, some
practitioners monitor therapy using unstimulated basal LH
levels. Our data demonstrate that this practice should be
used cautiously, particularly in the ﬁrst year of therapy, when
basal LH levels are routinely elevated above prepubertal
norms [20, 21, 24]. Like peak LH, basal LH showed a
downward trend during treatment, with the mean falling to
approximately 0.3IU/L by 24 weeks. However, many subjects
with suppressed peak LH exhibited basal LH concentrations
in the 0.5–1IU/L pubertal range.8 International Journal of Pediatric Endocrinology
Despite the high peak LH threshold required for study
entry, 33% of girls did not have detectable estradiol at base-
line, demonstrating its limited utility for diagnosis of CPP.
This is plausibly attributable to assay threshold or to physi-
ologic variability. The study RIA measured to 18.36pmol/L
(5pg/mL), whereas estradiol can now be measured by
MS/MS to approximately 7.34pmol/L (2pg/mL). Even that
threshold is well above normal prepubertal levels [25], and
as a consequence estradiol was not detectable during the
treatment phase of our study. Estradiol measurement during
therapy can at best conﬁrm complete treatment failure.
T h et e s t o s t e r o n eR I Ai no u rs t u d ym e a s u r e dt o
0.347nmol/L (10ng/dL), close to the prepubertal threshold
reported for MS/MS. For reasons of assay sensitivity, testos-
terone can generally be considered a better screen of CPP
(in combination with conﬁrmatory LH) in males compared
with estradiol in females. Testosterone levels fell steeply after
the ﬁrst injection, but 5/6 males intermittently exceeded
the prepubertal norm, despite suppressed LH levels. This
presents a clinical management dilemma whether to accept
marginally detectable testosterone levels, which may not
respond to more aggressive dosing. Alternative explanations
for incompletely suppressed testosterone include assay inac-
curacy in the lower range, testosterone of adrenal origin,
or persistent gonadal testosterone secretion despite apparent
gonadotropin suppression.
After discontinuation of treatment, subjects were fol-
lowedforanaverageof3.5years.Allsubjectshadresumption
of the pubertal hypothalamic-pituitary-gonadal axis within
12 months, and most by 6 months, with LH, FSH, and
estradiol or testosterone all returning to pubertal levels. The
resumption of puberty was also evidenced by progression
of Tanner stages in both females and males. In females,
the mean time to onset of menses was approximately 1.5
years,consistentwithpreviousstudiesinfemalestreatedwith
GnRHa, in which the interval ranged from 2 to 61 months,
with an average of approximately 16 months [6, 13, 26–28].
Furthermore, the mean age at the onset of menarche or re-
menarche in our study was 12.9 years, which is consistent
with the average age of menarche of 12.53 years in the US
[29]. Reassuringly, all females over 12 years old reported
menses by the end of the follow-up phase.
At callback of adult subjects we did not ﬁnd impairment
in reproductive function, consistent with previous studies
[6, 8, 13, 30]. A study by Heger et al. reported 12 pregnancies
in 34 women who wished to have children [6]. In the current
study, 7 women reported a total of 12 pregnancies. Although
deﬁnitiveconclusionregardinglong-termreproductivefunc-
tionisweakenedbythelimitednumberofpatientsthatcould
be located at callback more than a decade after the end of
treatment, the universal normalcy of hormone levels and
menses during the follow-up period and lack of reported
problems in adulthood are all reassuring.
In summary, treatment with leuprolide acetate 1-month
depot eﬀectively suppressed the GnRH axis for the duration
of therapy in all subjects. It was well tolerated, with no
clinically relevant injection-site reactions in any of the 55
subjects. Most subjects exhibited recovery to pubertal hor-
monelevels6monthsafterdiscontinuationoftreatment,and
mean onset of menses was 1.5 years after discontinuation.
Long-term follow-up and adult callback revealed that the
interruption of the GnRH axis in children with CPP did not
impair reproductive function in adulthood.
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